Novartis Says Remibrutinib Tops Teriflunomide in Two Phase III RMS Trials
Novartis reported that remibrutinib cut annualized relapse rates by 35.2% and 31.2% versus teriflunomide in two Phase III RMS trials. It also showed a 29.2% nominal reduction in 6mCDP risk, with no liver safety signal; Novartis plans to seek global regulatory approval.